# A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

> **NCT03754049** · PHASE2 · COMPLETED · sponsor: **Taiwan Liposome Company** · enrollment: 102 (actual)

## Conditions studied

- Osteoarthritis of the Knee

## Interventions

- **DRUG:** TLC599
- **DRUG:** DSP

## Key facts

- **NCT ID:** NCT03754049
- **Lead sponsor:** Taiwan Liposome Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-21
- **Primary completion:** 2023-11-07
- **Final completion:** 2023-11-07
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03754049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03754049, "A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03754049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*